Cardiopulmonary Exercise Testing in Fabry Disease: is It an Early Marker of Cardiomyopathy?
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Pieroni M, Namdar M, Olivotto I, Desnick R
. Anderson-Fabry disease management: role of the cardiologist. Eur Heart J. 2024; 45(16):1395-1409.
DOI: 10.1093/eurheartj/ehae148.
View
2.
De Marco O, Gambardella J, Bianco A, Fiordelisi A, Cerasuolo F, Buonaiuto A
. Cardiopulmonary determinants of reduced exercise tolerance in Fabry disease. Front Cardiovasc Med. 2024; 11:1396996.
PMC: 11096481.
DOI: 10.3389/fcvm.2024.1396996.
View
3.
Guazzi M, Bandera F, Ozemek C, Systrom D, Arena R
. Cardiopulmonary Exercise Testing: What Is its Value?. J Am Coll Cardiol. 2017; 70(13):1618-1636.
DOI: 10.1016/j.jacc.2017.08.012.
View
4.
Del Franco A, Iannaccone G, Meucci M, Lillo R, Cappelli F, Zocchi C
. Clinical staging of Anderson-Fabry cardiomyopathy: An operative proposal. Heart Fail Rev. 2023; 29(2):431-444.
DOI: 10.1007/s10741-023-10370-x.
View
5.
Roy A, Thompson S, Hodson J, van Vliet J, Condon N, Alvior A
. Changes in peak oxygen consumption in Fabry disease and associations with cardiomyopathy severity. Heart. 2024; 111(5):230-238.
PMC: 11874315.
DOI: 10.1136/heartjnl-2024-324553.
View